We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Spanish Biotech Biotools B&M Labs, S.A. Obtains U.S. Patent for its Gelification Technology
Product News

Spanish Biotech Biotools B&M Labs, S.A. Obtains U.S. Patent for its Gelification Technology

Spanish Biotech Biotools B&M Labs, S.A. Obtains U.S. Patent for its Gelification Technology
Product News

Spanish Biotech Biotools B&M Labs, S.A. Obtains U.S. Patent for its Gelification Technology


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Spanish Biotech Biotools B&M Labs, S.A. Obtains U.S. Patent for its Gelification Technology"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Based on this technology, Biotools has developed and launched on the market a wide product catalogue providing significant advantages to users. Among others, the Gelification Technology allows users to work under the concepts “one tube-one reaction” and “Ready-to-use”, saving time with reduced handling and risk of cross contaminations, making possible the performance of amplification reactions  in places not meeting the usual requirements for molecular diagnostic procedures. Therefore, Gelification Technology enables and highly simplifies the development of point of care diagnostic systems and other portable devices.

This technology has been already transferred successfully to Brazilian Health System (through IBPM) in March 2010, enabling product development and solutions meeting the idiosyncrasies of epidemiology in Brazil in particular, and South America, in general.  Also, it has been transferred to the recently inaugurated joint venture in India (3B BlackBio Biotech India. Ltd.), in order to develop and commercialize diagnostic kits and research tools optimized for the growing public and private Indian Healthcare, R&D, and Agfood sector.

Advertisement